August 2nd 2020
Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
July 20th 2020
A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.
June 29th 2020
Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
June 26th 2020
The Committee for Medicinal Products for Human Use has recommended approval of Aybintio, a bevacizumab (Avastin) biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.
June 22nd 2020
Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.
June 11th 2020
The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
April 30th 2020
Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.
April 15th 2020
Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.